Fortress Biotech, Inc. to Post FY2027 Earnings of ($6.67) Per Share, HC Wainwright Forecasts (NASDAQ:FBIO)

Fortress Biotech, Inc. (NASDAQ:FBIO) – Equities research analysts at HC Wainwright issued their FY2027 earnings estimates for shares of Fortress Biotech in a research note issued to investors on Tuesday, April 9th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will earn ($6.67) per share for the year. The consensus estimate for Fortress Biotech’s current full-year earnings is ($5.12) per share.

Other analysts have also recently issued reports about the stock. Roth Mkm started coverage on shares of Fortress Biotech in a research note on Friday, March 15th. They issued a “buy” rating and a $10.00 target price on the stock. Alliance Global Partners assumed coverage on shares of Fortress Biotech in a research report on Tuesday, March 19th. They issued a “buy” rating and a $5.00 target price on the stock. Finally, StockNews.com cut shares of Fortress Biotech from a “hold” rating to a “sell” rating in a research report on Friday.

Fortress Biotech Stock Performance

NASDAQ FBIO opened at $1.82 on Thursday. Fortress Biotech has a 1 year low of $1.24 and a 1 year high of $12.75. The company has a debt-to-equity ratio of 38.42, a current ratio of 1.38 and a quick ratio of 1.26. The stock has a market capitalization of $35.02 million, a PE ratio of -0.22 and a beta of 1.51. The company’s 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $2.37.

Institutional Investors Weigh In On Fortress Biotech

Large investors have recently modified their holdings of the stock. Advisor Group Holdings Inc. boosted its stake in shares of Fortress Biotech by 113.0% during the 1st quarter. Advisor Group Holdings Inc. now owns 20,020 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 10,620 shares in the last quarter. Two Sigma Securities LLC bought a new stake in Fortress Biotech during the first quarter worth about $30,000. Wells Fargo & Company MN boosted its stake in Fortress Biotech by 49.3% during the fourth quarter. Wells Fargo & Company MN now owns 47,441 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 15,657 shares in the last quarter. BNP Paribas Arbitrage SA boosted its stake in Fortress Biotech by 495.0% during the second quarter. BNP Paribas Arbitrage SA now owns 39,636 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 32,974 shares in the last quarter. Finally, Envestnet Asset Management Inc. bought a new stake in Fortress Biotech during the first quarter worth about $33,000. Institutional investors own 96.51% of the company’s stock.

Fortress Biotech Company Profile

Fortress Biotech, Inc, a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne.